President Trump’s new push to move marijuana out of the federal government’s toughest drug category is forcing Washington to finally admit what millions of patients and states have said for years.
Quick Take
- Trump signed an executive order directing federal agencies to speed up the formal rulemaking needed to move marijuana from Schedule I to Schedule III.
- The order does not legalize recreational marijuana nationwide; it accelerates an administrative process already underway at DOJ and DEA.
- Federal health agencies previously cited medical use evidence and widespread practitioner recommendations as the basis for rescheduling.
- The order also launches new work on CBD/hemp rules and “real-world evidence” research, signaling tighter product standards rather than a free-for-all.
What Trump Actually Ordered—and What Hasn’t Happened Yet
President Donald Trump signed an executive order in mid-December 2025 directing the Attorney General and federal agencies to complete the rescheduling process “most expeditiously” under the Controlled Substances Act. The target is moving marijuana from Schedule I—reserved for drugs deemed to have no accepted medical use—into Schedule III, where it would sit alongside tightly controlled medicines with recognized medical applications.
BREAKING: Trump administration reclassifies medical marijuana under federal law.
Acting AG Todd Blanche signed the order shifting it from SCHEDULE I, a category of drugs with no medical use and high potential for abuse, to the much less strictly regulated SCHEDULE III.
While… pic.twitter.com/RdwcKQVw3r
— Fox News (@FoxNews) April 23, 2026
That distinction matters because some headlines and social posts describe the move as an immediate “reclassification.” The more precise reading is procedural: the order pressures the bureaucracy to finish rulemaking that still requires the normal administrative steps. In practice, the impact hinges on how quickly DOJ and DEA complete the process and how the final rule is written, enforced, and defended if challenged.
Why the Schedule I Label Became Harder to Defend
Federal law has treated marijuana as Schedule I since 1970, placing it in the same bucket as heroin even as medical programs spread across the country. By 2025, state-level medical marijuana laws covered dozens of jurisdictions, creating an ongoing conflict between state practice and federal theory. The rescheduling push draws heavily on federal health reviews that concluded there is credible evidence for medical uses.
Those reviews also pointed to the size of the existing medical system. Federal health analysis referenced tens of thousands of practitioners recommending marijuana to millions of patients across a range of conditions. That does not mean marijuana is harmless, and it does not settle every question about long-term effects. It does, however, undercut the federal government’s long-standing claim that marijuana has “no accepted medical use.”
The Rulemaking Backstory: Science Moved First, Government Lagged
The current pathway did not start with Trump’s December order. Federal health agencies evaluated evidence in 2023, and DOJ issued a proposed rule in 2024 that attracted roughly 43,000 public comments. Then the process slowed, leaving patients, businesses, researchers, and states in a familiar place: waiting on a federal bureaucracy that struggles to deliver clear answers. Trump’s directive is best understood as a lever to restart a stalled process.
For conservatives who are skeptical of sprawling federal power, the irony is hard to miss. The same centralized system that insists on controlling drug scheduling can also delay reforms supported by evidence, public input, and state reality. Trump’s order does not eliminate the federal role, but it uses executive authority to force the administrative state to make a decision rather than drift—an approach many voters see as overdue across multiple policy areas.
What Schedule III Could Change for Patients, Research, and Business
Moving marijuana to Schedule III would still keep it federally controlled, but it could reduce barriers that come with Schedule I status—especially for medical research. Researchers have long argued that Schedule I classification creates red tape that limits rigorous trials, slowing the development of standardized, FDA-style answers about dosing, safety, and effectiveness. The order also emphasizes expanding medical marijuana and cannabidiol research, including “real-world evidence” efforts.
Economic effects are harder to pin down because they depend on implementation details not resolved by the order alone. Still, rescheduling could ease some operational constraints that stem from the federal government treating marijuana as Schedule I, while leaving major questions about recreational markets to state law and future congressional action. Conservatives and liberals alike may see this as a test of whether Washington can modernize policy without turning it into another sprawling, loosely enforced regime.
CBD, Hemp, and the Bigger Fight Over Regulation
One of the most consequential parts of the order may be less visible: the parallel push to build a clearer framework for hemp and CBD products, including THC-related thresholds and product ratios. Since the 2018 Farm Bill expanded legal hemp, the market has exploded, and consumers often face confusing labeling and uneven standards. The Trump order signals an intent to clarify rules rather than ignore the problems created by patchwork enforcement.
Politically, the move creates unusual coalitions. Civil-liberties groups praised the step as better alignment with science and state reality, even while broader debates continue over public health, youth access, and commercialization. Trump’s message—medical access paired with caution about abuse—aims for that middle ground. The unresolved question is whether federal agencies can implement a tighter, evidence-driven system without drifting into either legalization-by-neglect or prohibition-by-bureaucracy.
Sources:
ACLU responds to President Trump’s announcement rescheduling marijuana
Increasing Medical Marijuana and Cannabidiol Research
